| abstract |
The present application provides a method of producing a modified T cell with down-modulated endogenous T cell receptor (TCR). The present application also provides a method of producing a modified T cell with down-modulated endogenous TCR, further expressing a functional exogenous receptor, such as an engineered TCR (e.g., chimeric TCR), T cell antigen coupler (TAC), TAC-like chimeric receptor, or a chimeric antigen receptor (CAR). Further provided are modified T cells produced by the methods described herein, which may elicit reduced graft-versus-host disease (GvHD) response in a histoincompatible individual. Pharmaceutical compositions, kits, and methods of treatment are also provided. |